<div id="readability-page-1">04:16 AM EST, 12/15/2025 (MT Newswires) -- Johnson &amp; Johnson ( JNJ ) said late Friday that the US Food and Drug Administration has approved the supplemental new drug application for Akeega plus prednisone for the treatment of patients with a certain indication of metastatic castration-sensitive prostate cancer.The approval was based on positive results from a phase 3 clinical study in which the drug combination significantly reduced the risk of radiographic progression or death by 54% compared with a placebo, the company said. It also prolonged the time to symptomatic progression by 59%, the company said.The safety profile of the combination was consistent with other FDA-approved therapies, the company said.Prostate cancer patients with the indication, called a BRCA mutation, often have more aggressive forms of the disease, the company said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

強生

強生宣佈其前列腺癌療法 Akeega 聯合潑尼松獲得 FDA 批准，針對帶有 BRCA 突變的轉移性去勢敏感性前列腺癌。該批准基於一項三期研究，顯示放射學進展或死亡風險降低 54%，症狀進展延遲 59%。其安全性特徵與其他 FDA 批准的療法一致

強生的前列腺癌治療申請已獲美國 FDA 批准